Why personal genomics company 23andMe now worth more than $1 billion

Genetic analytics company 23andMe reported via a regulatory filing that it had raised $79 million in a Series E venture capital round that could eventually hit $150 million. Market research firm VC Experts subsequently pulled Delaware filings that show the round was done at a post-money valuation of approximately $1.03 billion (based on the $79m, not the $150m).

That’s nearly a 2.7x valuation jump from 23andMe’s Series D raise, which occurred in late 2012. Investors on that round included Google Ventures, New Enterprise Associates, MPM Capital and Yuri Milner.

So how do we explain the valuation jump, particularly given that 23andme last year was dealt a severe blow when the FDA said it could no longer market its personalized DNA testing kit for health reports to U.S. consumers?

Related on the SLP

23andMe moves to mend fences with FDA, seeks Bloom syndrome test approval Will FDA regulations force US direct-to-consumer genetic testing companies overseas?

Viewpoint: Democratic tsunami: As the red tide recedes, here are the most likely shifts in food and agricultural policy

$7.35 billion PFAS settlement: 3M to pay people who blame health problems on ‘forever chemicals’ phased out of firefighting foam for more than 20 years

Collagen supplements are not a wrinkle-reducing silver bullet, but they sure cost a lot

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis. Read full, original post: 23andMe is the startup world’s newest unicorn